Ignite Creation Date:
2025-12-25 @ 2:19 AM
Ignite Modification Date:
2026-03-02 @ 4:22 PM
Study NCT ID:
NCT02972034
Status:
TERMINATED
Last Update Posted:
2024-11-21
First Post:
2016-11-21
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-01-13
Start Date Type:
ACTUAL
Primary Completion Date:
2022-12-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-12-02
Completion Date Type:
ACTUAL
First Submit Date:
2016-11-21
First Submit QC Date:
None
Study First Post Date:
2016-11-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-11-22
Results First Submit QC Date:
None
Results First Post Date:
2024-11-21
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-13
Last Update Post Date:
2024-11-21
Last Update Post Date Type:
ACTUAL